Patients
Patient Support ProgramPatient Stories
How Altius Works
Healthcare Providers
The Altius® SystemClinical ResultsClinical LiteratureInstructions for Use
FAQ
See if you qualify

Who we are

Dedicated to amputees and the healthcare professionals who care for them.

About Neuros

There are nearly two million amputees in the U.S., with 300,000 new amputations occurring every year.1 Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.2 Neuros Medical is a privately held company and the maker of the Altius System which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to relieve pain and restore life for people suffering with post-amputation pain. We are a passionate team guided by our core values and committed to patients and the healthcare professionals who care for them.

‍Our Core Values: Patients First, Team Before Self, Humility, Accountable, Deliver Excellence.

The Board of Directors

Fouad Azzam, Ph.D.

EQT Life Sciences

Read more about Fouad

Joyce Erony

Amzak Capital Management

Read more about Joyce

Bill Harrington, M.D.

Osage University Partners

Read more about Bill

Marc-André Marcotte

Sectoral Asset Management

Read more about Marc

Casey Tansey

U.S. Venture Partners

Read more about Casey

David Veino

President and CEO

Randy Ban

Chief Commercial Officer at Inspire Medical, Independent Director

Management

David Veino

President and CEO

David was named President and CEO of Neuros in 2023, after serving as Chief Operating Officer since 2018.

Prior to Neuros, David worked for Cardiovascular Systems, Inc. (CSII), where he held a variety of senior executive positions and scaled the commercial organization from $50M in peripheral sales to over $250M in combined coronary and peripheral sales. During his tenure, David led the successful development of amputation prevention programs designed to drive awareness and access to care for underserved communities in the United States.

Prior to CSI, David served as General Manager for Stryker (SYK), where he led the creation of the Interventional Spine Division. David has also held key commercial leadership positions with Globus Medical (GMED) and other venture capital medical device companies.

David serves as a private equity advisor with Sectoral Asset Management. He earned a BS in Physiology from Chico State University and completed the Advanced Management Program at Harvard Business School.

Tom Tovello

Chief Financial Officer

Tom brings extensive executive leadership experience navigating complex capital structures, M&A, and corporate scaling across the healthcare and medtech landscapes.

Over his career, Tom has partnered with leading venture capital firms and strategic partners to capitalize emerging growth companies, raising significant institutional and non-dilutive funds. His transactional track record includes guiding Endotronix through its strategic acquisition by Edwards Lifesciences, alongside prior portfolio leadership within PACK Pharmaceuticals and private family office platforms. Tom focuses on constructing scalable financial infrastructure and high-performing teams that turn emerging healthcare innovations into sustainable businesses.

Tom is a certified public accountant (currently inactive) who earned a bachelor’s degree in accounting and finance from Eastern Illinois University, followed by a Master of Business Administration from Northern Illinois University.

Steve Bosrock

Vice President of Marketing

Steve brings 20 years of medical device leadership experience building and leading successful commercial teams and launching disruptive products to his new role at Neuros Medical.  He was most recently the Vice President of Marketing and Medical Education for Apollo Endosurgery through the acquisition by Boston Scientific in 2023.  Prior to Apollo, he held various commercial leadership roles with small privately held and publicly traded companies including Torax Medical (acquired by Johnson & Johnson) and Synovis Life Technologies (acquired by Baxter).

Steve holds a Master of Business Administration degree from the Ross School of Business at the University of Michigan and a bachelor’s degree from Boston College.

Blair Canale

Vice President of Sales

Blair brings 25+ years of experience in the medical industry, heavily focused in the areas of vascular and cardiovascular disease states. He joins most recently from Endologix, where he served as the Eastern US Sales Manager.  Prior to Endologix, he served as Coronary Sales Director for Abbott Vascular.

Blair has launched numerous disruptive technologies, serving physicians and the patients that they treat in various leadership roles. He graduated from the University of Alabama with a bachelor’s degree in Public Relations and a minor in Marketing.

Michael Fonseca

Vice President of R&D

Michael has over 25 years of experience developing and commercializing medical technologies in both start-up and corporate environments. Prior to joining Neuros Medical, he served as Vice President of Product Development at StethX, Inc., an early-stage start-up. He also held the role of Director of Product Development for CardioMEMS at Abbott, where he was the first engineer and key technical expert behind the platform’s remote heart failure monitoring technology, leading its development from concept through commercialization.

Michael also serves as adjunct faculty at The Georgia Institute of Technology and Emory University’s Wallace H. Coulter Department of Biomedical Engineering. He holds ten issued patents and has successfully launched innovative products in cardiology and aortic aneurysm treatment throughout his career. He earned his Ph.D. in Electrical Engineering from The Georgia Institute of Technology in the field of wireless MEMS pressure sensors, which became foundational research for the CardioMEMS platform. Michael also received his M.S. and B.S. degrees in Electrical Engineering from The Georgia Institute of Technology.

Nick Hargus, Ph.D.

Vice President of Clinical and Medical Affairs

Nick joined Neuros in 2022.

Prior to Neuros, Nick was at Cardiovascular Systems, Inc. (CSII), where he last served as the Director of Medical Affairs, responsible for scientific communication and patient safety. During his 8-year tenure, Nick was responsible for the creation of a Medical Science Liaison program and provided medical affairs expertise to support the acquisition, approval, and launch of new products.

Prior to industry, Nick had a 10+ year career in academic science with appointments at the National Institutes of Health, University of Virginia, and University of Minnesota.

Nick earned his PhD in Neuroscience from the University of Virginia, where he studied sodium channel function and gating alterations in epilepsy and chronic pain. His work resulted in numerous peer-reviewed publications funded through multiple individual NIH-supported grants. He received his BS in Neuroscience from Lafayette College.

Kimberly Konopa, MBA

Vice President of Market Access & Reimbursement

Kimberly comes to Neuros Medical with over 30 years of experience in the pharmaceutical, biotechnology, and medical device industries, specializing in health economics, coding, coverage, and payment strategies that accelerate patient access to innovative technologies.

Prior to joining Neuros, Kimberly served as Vice President of Market Access & Reimbursement at Inspire Medical Systems, where she led the national market access strategy and reimbursement infrastructure for implantable neurostimulation therapy. Over her career, she has held key commercial and market access leadership roles at major medical technology and life sciences companies—including Medtronic, Philips, and Johnson & Johnson—as well as high-growth startups such as Intersect ENT.

Kimberly holds a Master of Business Administration in Strategic Business Planning and a Bachelor of Science in Business / Marketing, both from the Indiana University Kelley School of Business.

Important safety information

1. Prevalence of Limb Loss and Limb Difference in the United States: Implications for Public Policy. Caruso and Harrington 2024 Avelere Report.

2. Erlenwein, J., Diers, M., Ernst, J., Schulz, F., & Petzke, F. (2021). Clinical updates on phantom limb pain. Pain reports, 6(1), e888.

This information is for informational purposes only, is not medical advice or a diagnosis, and is not a substitute for professional medical advice. Consult with your healthcare provider regarding your condition. Individual symptoms, circumstances, and results vary.

Indications for use

The Altius® Direct Electrical Nerve Stimulation System is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees.

Contraindications

The Altius System is contraindicated for patients who are: Unable to operate the system or Unsuitable for the Altius implant surgery.

Warnings/Precautions

Use as indicated and instructed. Diathermy should not be used on patients with the Altius System, or any of its components, either as a treatment for a medical condition or as part of a surgical procedure. Electromagnetic interference (EMI) is a field of energy generated by equipment found in the home, work, medical, or public environments that is strong enough to interfere with Altius System function. The electrical pulses from the Altius System may interact with the sensing operation from a cardiac device and could result in an inappropriate response of the cardiac device; physicians involved should discuss the possible interactions between the devices before surgery. Safety and effectiveness of the Altius System for pediatric use and for pregnant patients has not been established. Surgical complications and adverse events may be more frequent and severe in diabetic patients. Safety of MRI/NMRI with an implanted Altius System has not been evaluated. Patients implanted with the Altius System, or any of its components, should not be subject to MRI/NMRI. See Instructions for Use for detailed information regarding the procedure(s), indications, contraindications, warnings, precautions, and potential adverse events before performing the Altius procedure. For more information and to view full Instructions for Use, visit www.neurosmedical.com.

Although FDA has determined that the probable benefits outweigh the probable risks, there remains some uncertainty regarding the manufacturer’s human factors engineering (HFE) and usability engineering (UE) analysis and validation testing. As a condition of approval, FDA is requiring the manufacturer to provide an HFE/UE analysis and validation testing and recommending that this analysis and testing is designed using the FDA’s 2016 guidance document “Applying Human Factors and Usability Engineering to Medical Devices” (https://www.fda.gov/media/80481/download).

Rx Only.

Patients
How Altius® WorksPatient Support ProgramPatient StoriesFAQContactUnderstanding Phantom Limb Pain
Healthcare Providers
The Altius® SystemClinical ResultsClinical LiteratureInstructions for UseGet in Touch
About & Contact
About UsCertificationNewsEmployment

1212 Red Fox Rd
Arden Hills, MN 55112

Phone: (440) 951-2565
© Neuros Medical Inc 2026 | All rights reserved.
Privacy PolicyTerms of ServiceCookie PolicyConsent Preferences
Rx Only
LB-0216 Rev P